Why acquisition cost means something different in pharma marketing

In 2015 Gilead Sciences' hepatitis C franchise brought in roughly $19 billion. Within a few years it was a fraction of that. The marketing had not failed. The drugs cured people, and cured people stop refilling. That is the extreme version of something every prescription brand lives with: the person you spend money to reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition →, the person who takes the drug and the person who pays for it are three different people, and revenue only arrives when all three keep saying yes, month after month. An acquisition costacquisition costCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.View full definition → that counts the first yes and stops there is pricing the cheapest part of the sale.

Three parties, one number

Consumer CAC is clean: total spend divided by new paying customers. One person clicks, buys, becomes a customer. Pharma breaks that chain in three places.

• The buyer is not the customer. The HCP (physician, nurse practitioner or other licensed prescriber) decides to prescribe, the patient fills and keeps filling, and the payer decides how much of list price survives into net revenue. You can win the prescriber outright and still collect very little.
• The channel mix is fixed before you optimise anything, in the ways the lesson on promoting under heavy regulation sets out. Some line items cannot exist in your spend table at all, and every asset that does exist carries a review cost you cannot cut.
• The cycle is long and multi-touch. One prescriber's decision may follow a rep visit, a speaker program dinner, a congress booth and three emails, spread across 12 to 18 months.

Building cost-per-HCP-reached

The pharma equivalent of cost-per-impressionimpressionThe total number of times an ad or piece of content is displayed, regardless of clicks. Each display counts as one impression, even to the same person.View full definition →, but the impression is a named, licensed individual.

Cost per HCP reached = Total promotional spend / Number of unique HCPs contacted

Inputs usually bundled into "promotional spend":

• Field force cost: rep salaries, benefits, training, territory management. A US pharma rep fully loaded runs somewhere around $150,000 to $200,000 a year on recent industry estimates, which puts a single detail (an in-person visit presenting approved drug data) at $200 to $300.
• Speaker programs: physician honoraria, venue, meals, all publicly disclosed.
• Digital and non-personal promotion: banner and email inventory on prescriber networks such as Doximity, which sells exactly this inventory and reports membership covering the large majority of US physicians.
• Congress sponsorship: booths, satellite symposia, print journal placement.

Worked example. A mid-size specialty brand spends $8 million a year across a 150-person field force, digital HCP campaigns and 40 regional speaker programs. Its CRMCRMCustomer Relationship Management: software and strategy to manage and analyse customer interactions throughout their lifecycle.View full definition → shows 12,000 unique HCPs contacted at least once, tracked by NPI (National Provider Identifier, the unique ID for US prescribers).

$8,000,000 / 12,000 HCPs = $667 cost per HCP reached

A packaged goods marketer paying $5 to $15 per thousand impressions will find that grotesque. The comparison is empty: one of these buys an anonymous eyeball, the other buys a conversation with someone who writes for hundreds of patients a year.

Building cost-per-NRx

NRx is a new prescription, a patient starting therapy. TRx is total prescriptions including refills. NRx is the leading indicator because it shows behaviour changing rather than an existing base continuing.

Cost per NRx = Total spend / Incremental NRx attributable to promotion

The load-bearing word is "attributable". Most US brands count scripts from IQVIA's prescription data (IQVIA sells both the data and the analytics layered on it), then run market mix modeling to separate promotional lift from baseline demand, seasonality, competitor launches and formulary changes.

Illustration. A brand writes 50,000 NRx in a quarter. The model attributes 30% to promotion. Quarterly spend is $6 million.

Incremental NRx = 50,000 x 0.30 = 15,000
Cost per NRx = $6,000,000 / 15,000 = $400

From cost per script to cost per persistent patient

$400 per new script is not $400 per patient, because a large share of those scripts never become revenue. Some are never filled at the counter, and many more lapse within months, the drop-offs the funnelfunnelThe customer journey from awareness to purchase, typically Awareness, Interest, Consideration, Decision, Action, with prospects narrowing at each stage.View full definition → lesson maps stage by stage. Fold both into the denominator:

Cost per persistent patient = Spend / (NRx x fill rate x persistence at month 12)

With a 0.80 fill rate and 40% still on therapy at twelve months:

15,000 x 0.80 x 0.40 = 4,800 persistent patients
$6,000,000 / 4,800 = $1,250 per persistent patient

Three times the headline number, from the same spend and the same scripts. Now the consequences.

Two channels with identical cost per NRx can be far apart here. A speaker program that convinces a specialist to titrate carefully and book a six-week follow-up produces a different survival curve than a copay voucher that buys a first fill from an ambivalent patient. Rank your channels on cost per NRx and you will systematically overfund the ones that produce fragile starts.

Retention spend gets reclassified. AbbVie runs a patient support program behind Humira (nurse ambassadors, injection training, benefits and copay help), the kind of infrastructure self-injectable brands use to hold patients through the first weeks when injection anxiety and early side effects drive people off therapy. Humira cleared $20 billion globally in 2022. Support programs generate zero new prescriptions, so under cost per NRx they sit in overhead and get cut in a bad quarter. Under cost per persistent patient they are acquisition spend, and cutting them raises your true CAC. That reclassification is the practical output of this lesson.

The comp plan usually blocks it. Field incentive compensation is typically tied to script volume in territory, so reps are paid on the cheap half of the number. Changing the metric on the dashboard while leaving the bonus formula alone changes nothing.

Two edge cases where the denominator is wrong from the start. Curative or fixed-duration therapy inverts the model: Gilead's hepatitis C regimens are twelve weeks, so the unit is a completed course, persistence past that point is not the goal, and the brand needs a genuinely new patient for every unit of revenue forever. Second, persistence is partly a payer variable. A brand pushed from preferred to non-preferred tier at one large PBM can watch its persistence curve bend on patients it already acquired, inflating cost per persistent patient retroactively with no change in marketing at all. Compute the metric by payer segment, or it will move for reasons your team did not cause and cannot fix.

Why the benchmark comparison misleads

• Lifetime valueLifetime valueLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → sits on the other side of the ratio and behaves nothing like a consumer subscription, in the ways the LTV lesson models. The SaaS 3:1 rule of thumb has no meaning against a molecule with a patent cliff.
• One HCP touch generates many downstream transactions. Consumer CAC is one ad, one buyer. One detail can shift prescribing for dozens of patients in a quarter.
• Compliance cost is structural, not overhead. MLR review of every asset, payment disclosure infrastructure and pharmacovigilance obligations are fixed costs consumer marketers never carry.

For a grounded look at how HCP engagement channels are shifting, the Accenture Life Sciences digital engagement research tracks how much prescriber interaction has moved to remote and digital channels since 2020, a structural change in the cost base.

What good actually looks like

Real figures are closely guarded, but directionally, on recent industry estimates:

• Rare disease and oncology brands accept cost-per-NRx in the thousands, sometimes tens of thousands, because the prescriber base is small and per-patient value is very high.
• Primary care brands target the low hundreds, because volume is the lever.
• European affiliates run lower per-HCP spend than the US, with smaller field forces and national pricing negotiations compressing commercial budgets. A German or French team often works the same molecule with a fraction of the US headcount.

Persistence rates vary by an order of magnitude across therapeutic areas, which the benchmarking lesson quantifies, so a cost per persistent patient is only readable next to the right comparator. Within one brand, the number worth reporting to a board is the trend: cost per NRx should fall as peer influence among prescribers takes over work that paid promotion used to do alone, and the gap between cost per NRx and cost per persistent patient should narrow as adherence support matures. If the gap widens while scripts grow, you are buying starts and losing patients.

🎬 [VIDEO: "How Pharma Companies Market to Doctors" - youtube.com - search for recent explainers from health policy channels like Healthcare Triage covering rep detailing, speaker programs and Sunshine Act disclosure mechanics]

Key Takeaways

• Cost per NRx prices a script, cost per persistent patient prices the asset. Divide by fill rate and 12-month persistence and the real number is routinely two to three times the headline.
• Channels with matching cost per NRx can differ sharply once persistence is folded in, so ranking spend on scripts alone overfunds fragile starts.
• Patient support and adherence programs produce no new prescriptions and look like overhead on the wrong metric. On the right one they are acquisition spend.
• Changing the metric without changing field incentive compensation changes nothing, because reps are still paid on the cheap half of the number.
• Curative and fixed-duration regimens invert the model, and a formulary tier move can inflate your cost per persistent patient with no change in marketing at all.